Episode 55: Blockchain and Decentralized Data – The Future of Healthcare

Leah Houston Headshot

Episode 55: Blockchain and Decentralized Data – The Future of Healthcare

Leah Houston, MD, an emergency physician and founder of HPEC as well as Evercred, explains blockchain as a decentralizer of physician and patient data and how it will be applied ubiquitously across the healthcare system. Dr. Houston shares and makes the case for how blockchain stores medical data and keeps the ownership in the hands of physicians, offers a solution to issuing and maintaining digital credentials for healthcare professionals, and highlights how physician interest and involvement are crucial to “reclaiming ownership of the profession and our individual identities.”

Related Resources

Visit the HPEC website to receive your invitation here.

Visit Dr. Houston’s Evercred website here.

Subscribe to Healthcare Unfiltered

Other Episodes You May Enjoy...

Episode 223: From Lab to Statup: Dr. Simrit Parmar on Launching Cellenkos

Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous

Read More

Episode 222: Language Matters: A Patient Perspective

Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those

Read More

Episode 221: Major Progress in Adjuvant Renal Cell Carcinoma

Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease

Read More